Inicio › Cáncer de próstata › Ohio
Ensayos clínicos de Cáncer de próstata en Ohio
65 estudios sobre Cáncer de próstata buscan participantes en Ohio.
Ciudades en Ohio
- Cleveland34 estudios
- Columbus24 estudios
- Cincinnati18 estudios
- Akron9 estudios
- Toledo7 estudios
- Dayton7 estudios
- Youngstown4 estudios
- Chillicothe3 estudios
- Parma3 estudios
Texto oficial del estudio (inglés)
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Strecker Cancer Center-Belpre, Belpre
- Adena Regional Medical Center, Chillicothe
- Ohio State University Comprehensive Cancer Center, Columbus
- y 22 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT03866382Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Cente, Cleveland
ReclutandoFase 2
Edades de 19 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT06738303Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
- University Hospitals Cleveland Medical Center, Cleveland
Reclutando
Edades de 18 en adelante · Hombres · Actualizado el 28 sept 2026 · NCT06496256A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
- University Hospitals Cleveland Medical Center, Cleveland
ReclutandoFase 1
Edades de 18 en adelante · Hombres · Actualizado el 25 sept 2026 · NCT07082920A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
- University Hospitals Cleveland Medical Center, Cleveland
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07319871DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
ReclutandoEstudio observacional
Edades de 18 a 130 · Todos los sexos · Actualizado el 25 sept 2026 · NCT07124000A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- University Hospitals Cleveland Medical Center ( Site 0043), Cleveland
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06136650This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
- TriState Urologic Services PSC Inc. dba The Urology Group, Cincinnati
- University Hospitals Cleveland Medical Center, Cleveland
- y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 24 sept 2026 · NCT07028853Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- Central Ohio Urology Group, Gahanna
ReclutandoFase 2/3
Edades de 18 a 100 · Hombres · Actualizado el 22 sept 2026 · NCT06780670A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Oncology Hematology Care Incorporated, Cincinnati
- The Ohio State University, Columbus
- Dayton Physicians LLC Dayton, Dayton
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 22 sept 2026 · NCT07213674Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Urology Group - Solaris Network, Cincinnati
- Central Ohio Urology Group, Gahanna
ReclutandoFase 3
Edades de 18 a 100 · Hombres · Actualizado el 22 sept 2026 · NCT06855277A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, Columbus
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 18 sept 2026 · NCT06952803A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0061), Columbus
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 17 sept 2026 · NCT06925737Investigation of Impact of AI on Prostate Cancer Workflow
- Cleveland Clinic Foundation, Cleveland
Reclutando
Edades de 55 a 80 · Todos los sexos · Actualizado el 15 sept 2026 · NCT07084779MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
- University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
ReclutandoFase 2
Edades de 18 en adelante · Hombres · Actualizado el 15 sept 2026 · NCT06150417Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
- Oncology Hematology Care Incorporated, Cincinnati
ReclutandoFase 1
Edades de 18 en adelante · Hombres · Actualizado el 15 sept 2026 · NCT07493512The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT04585750Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- University Hospitals Cleveland, Cleveland
Reclutando
Edades de 18 en adelante · Hombres · Actualizado el 14 sept 2026 · NCT06511141Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Cleveland Clinic Akron General, Akron
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- y 27 más
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 10 sept 2026 · NCT05946213A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT06465069A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Solaris Health - The Urology Group, Cincinnati
ReclutandoFase 2
Edades de 18 en adelante · Hombres · Actualizado el 3 sept 2026 · NCT07005154A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
- Gabrail Cancer Center Research, Canton
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 3 sept 2026 · NCT07723248Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Aultman Health Foundation, Canton
- Ohio State University Comprehensive Cancer Center, Columbus
- ProMedica Flower Hospital, Sylvania
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 2 sept 2026 · NCT06931340Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- MetroHealth Medical Center, Cleveland
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 2 sept 2026 · NCT07200830Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- y 44 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 2 sept 2026 · NCT05334069The Vanguard Study: Testing a New Way to Screen for Cancer
- Louis Stokes Cleveland VA Medical Center, Cleveland
ReclutandoSe aceptan voluntarios sanos
Edades de 45 a 75 · Todos los sexos · Actualizado el 2 sept 2026 · NCT06995898Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- MetroHealth Medical Center, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT06632977AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Research Site, Cleveland
- Research Site, Dayton
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 26 ago 2026 · NCT07611110Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Oncology Hematology Care Incorporated, Cincinnati
ReclutandoFase 1
Edades de 18 en adelante · Hombres · Actualizado el 21 ago 2026 · NCT04221542A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
- The Ohio State University, Columbus
- Taylor Cancer Research Center, Maumee
ReclutandoFase 1/2
Edades de 18 en adelante · Hombres · Actualizado el 20 ago 2026 · NCT06785636Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 19 ago 2026 · NCT04423211A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- University Hospitals Cleveland Medical Center, Cleveland
ReclutandoFase 2
Edades de 18 en adelante · Hombres · Actualizado el 17 ago 2026 · NCT06842498FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
- Cleveland Clinic, Cleveland
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT05919264Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- University of Cincinnati Medical Center, Cincinnati
- The Ohio State University, Columbus
ReclutandoFase 1
Edades de 18 a 100 · Hombres · Actualizado el 13 ago 2026 · NCT05519449Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
- Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center, Cleveland
Reclutando
Edades de 19 en adelante · Hombres · Actualizado el 6 ago 2026 · NCT05610852Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
- The Ohio State University, Columbus
ReclutandoFase 1
Edades de 18 en adelante · Hombres · Actualizado el 31 jul 2026 · NCT06613100Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Hombres · Actualizado el 14 jul 2026 · NCT05691465Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Cleveland Clinic Akron General, Akron
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- y 15 más
ReclutandoFase 3
Edades de 18 en adelante · Hombres · Actualizado el 14 jul 2026 · NCT06592924A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
- The Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 1
Edades de 18 en adelante · Hombres · Actualizado el 9 jul 2026 · NCT07103018A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
- Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company, Cleveland
ReclutandoEstudio observacional
Edades de 18 en adelante · Hombres · Actualizado el 7 jul 2026 · NCT07406282De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.